A5002707023- SARS-CoV-2 and COVID-19 Research
- SARS-CoV-2 detection and testing
- COVID-19 Clinical Research Studies
- Respiratory viral infections research
- Animal Virus Infections Studies
- Computational Drug Discovery Methods
- COVID-19 epidemiological studies
- Plant Virus Research Studies
- Innovative Microfluidic and Catalytic Techniques Innovation
- Vaccine Coverage and Hesitancy
- Bacteriophages and microbial interactions
- Biosensors and Analytical Detection
- Electrostatic Discharge in Electronics
- Virus-based gene therapy research
- Influenza Virus Research Studies
- Viral gastroenteritis research and epidemiology
- vaccines and immunoinformatics approaches
- Viral Infections and Immunology Research
- Infection Control and Ventilation
- CRISPR and Genetic Engineering
- COVID-19 impact on air quality
The Francis Crick Institute
2024-2025
University College London Hospitals NHS Foundation Trust
2024
National Institute for Health Research
2024
University College London
2024
University of Bristol
2021-2023
The mechanistic factors hypothesized to be key drivers for the loss of infectivity viruses in aerosol phase often remain speculative. Using a next-generation bioaerosol technology, we report measurements aero-stability several SARS-CoV-2 variants concern droplets well-defined size and composition at high (90%) low (40%) relative humidity (RH) upwards 40 min. When compared with ancestral virus, Delta variant displayed different decay profiles. At RH, viral approximately 55% was observed over...
Abstract Background The mutational landscape of SARS-CoV-2 varies at the dominant viral genome sequence and minor genomic variant population. During COVID-19 pandemic, an early substitution in was D614G change spike protein, associated with increase transmissibility. Genomes are accompanied by a P323L polymerase (NSP12). However, is not thought to be under strong selective pressure. Results Investigation P323L/D614G substitutions population shows rapid emergence during containment phase...
Abstract The mutational landscape of SARS-CoV-2 varies at both the dominant viral genome sequence and minor genomic variant population. An early change associated with transmissibility was D614G substitution in spike protein. This appeared to be accompanied by a P323L polymerase (NSP12), but this latter not under strong selective pressure. Investigation P323L/D614G changes human population showed rapid emergence during containment phase surge wave 1 UK. from variants become part sequence. A...
Abstract SARS-CoV-2 is the aetiologic agent of COVID-19 and associated ongoing pandemic. As pandemic has progressed, Variants Concern (VOC) have emerged with lineage defining mutations. Using a reverse genetic system, based on transformation recombination in yeast, series replicons were produced for ancestral Wuhan virus VOC Delta which different combinations Spike, membrane, ORF6 ORF7a coding sequences replaced encoding selectable marker puromycin N-acetyl transferase reporter proteins (...
Coronaviruses pose a permanent risk of outbreaks, with three highly pathogenic species and strains (SARS-CoV, MERS-CoV, SARS-CoV-2) having emerged in the last twenty years. Limited antiviral therapies are currently available their efficacy randomized clinical trials enrolling SARS-CoV-2 patients has not been consistent, highlighting need for more potent treatments. We previously showed that cobicistat, clinically approved inhibitor Cytochrome P450-3A (CYP3A), direct activity against early...
Abstract Emerging SARS-CoV-2 variants require rapid assessments of pathogenicity and evasion existing immunity to inform policy. A crucial component these is accurate estimation serum neutralising antibody titres using cultured live virus isolates. Here, we report our updated culture methods for Omicron sub-variant JN.1 Caco-2 cells the subsequent evaluation (nAbTs) in recipients BNT162b2-XBB.1.5 monovalent Ancestral/BA.5 containing bivalent vaccines. We compared either Vero V1 or cells,...
Abstract Influenza remains a significant threat to human and animal health. Assessing serological protection against influenza has relied upon haemagglutinin inhibition assays, which are used gauge existing immune landscapes, seasonal vaccine decisions in systems vaccinology studies. Here, we adapt our high-throughput live virus microneutralisation assay for SARS-CoV-2, benchmark report responsiveness cohort of older (>65yo) community dwelling adults (n=73), after the adjuvanted 2021-22...
Abstract SARS-CoV-2 has been proposed to encode ORF10 as the 3’ terminal gene in viral genome. However, potential role and even existence of a functional product subject debate. There are significant structural features genomic RNA that could, by themselves, explain retention nucleotide sequences without need for protein product. To explore this question further we made two recombinant viruses, firstly control virus (WT) based on genome sequence original Wuhan isolate with inclusion early...
Abstract Coronaviruses pose a permanent risk of outbreaks, with three highly pathogenic species and strains (SARS-CoV, MERS-CoV, SARS-CoV-2) having emerged in the last twenty years. Limited antiviral therapies are currently available their efficacy randomized clinical trials enrolling SARS-CoV-2 patients has not been consistent, highlighting need for more potent treatments. We previously showed that cobicistat, clinically approved inhibitor Cytochrome P450-3A (CYP3A), direct activity against...